Butyrate acts synergistically with βOHB to reduce intestinal inflammation in paediatric IBD and inhibit HDAC, reduce inflammatory cytokine production, and increase histone H3 acetylation in macrophages. Here, HDAC9 is linked to inflammatory bowel disease.